Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launchGREENFIELD, Ind., Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway."This is an exciting time at Elanco as we deliver a robust innovation portfolio that we believe will help trans ...